Paraganglioma and phaeochromocytoma: From genetics to personalized medicine

Nature Reviews Endocrinology

Volumn 11, Issue 2, 2015, Pages 101-111

  Favier, Judith ^a   Amar, Laurence ^b   Gimenez Roqueplo, Anne Paule ^c  

^a PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXOGLUTARIC ACID; HISTONE DEMETHYLASE; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE; TRANSCRIPTOME;

DNA METHYLATION; GENE EXPRESSION PROFILING; GENETIC SCREENING; GENETICS; GERMLINE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; LEIOMYOMATOSIS; MULTIPLE ENDOCRINE NEOPLASIA; NEUROFIBROMATOSIS; PARAGANGLIOMA; PERSONALIZED MEDICINE; PHENOTYPE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; REVIEW; SOMATIC MUTATION; VON HIPPEL LINDAU DISEASE; ADRENAL TUMOR; NEUROENDOCRINE TUMOR; PATHOLOGY; PROCEDURES;

ADRENAL GLAND NEOPLASMS; HUMANS; NEUROENDOCRINE TUMORS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PRECISION MEDICINE;

EID: 84923081697     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2014.188     Document Type: Review

References (94)

1. Baysal, B. E. et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287, 848-851 (2000).
2. Astuti, D. et al. Germline SDHD mutation in familial phaeochromocytoma. Lancet 357, 1181-1182 (2001).
3. Dluhy, R. G. Pheochromocytoma - death of an axiom. N. Engl. J. Med. 346, 1486-1488 (2002).
4. Pacak, K. et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat. Clin. Pract. Endocrinol. Metab. 3, 92-102 (2007).
5. Dahia, P. L. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat. Rev. Cancer 14, 108-119 (2014).
6. Buffet, A. et al. A decade (2001-2010) of genetic testing for pheochromocytoma and paraganglioma. Horm. Metab. Res. 44, 359-366 (2012).
7. Viskochil, D. et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 62, 187-192 (1990).
8. Gutmann, D. H. et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278, 51-57 (1997).
9. Walther, M. M., Herring, J., Enquist, E., Keiser, H. R. & Linehan, W. M. von Recklinghausen's disease and pheochromocytomas. J. Urol. 162, 1582-1586 (1999).
10. Bausch, B. et al. Comprehensive mutation scanning of NF1 in apparently sporadic cases of pheochromocytoma. J. Clin. Endocrinol. Metab. 91, 3478-3481 (2006).
11. Bausch, B. et al. Clinical and genetic characteristics of patients with neurofibromatosis type 1 and pheochromocytoma. N. Engl. J. Med. 354, 2729-2731 (2006).
12. Hersh, J. H. et al. Health supervision for children with neurofibromatosis. Pediatrics 121, 633-642 (2008).
13. Burnichon, N. et al. Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Hum. Mol. Genet. 21, 5397-5405 (2012).
14. Mulligan, L. M. et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363, 458-460 (1993).
15. Wagner, A. J. et al. Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors. Mod. Pathol. 26, 289-294 (2013).
16. Brandi, M. L. et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab. 86, 5658-5671 (2001).
17. American Thyroid Association Guidelines Task Force. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19, 565-612 (2009).
18. Latif, F. et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260, 1317-1320 (1993).
19. Maher, E. R., Neumann, H. P. & Richard, S. von Hippel-Lindau disease: a clinical and scientific review. Eur. J. Hum. Genet. 19, 617-623 (2011).
20. Castro-Vega, L. J. et al. Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. Hum. Mol. Genet. 23, 2440-2446 (2014).
21. Amar, L. et al. Genetic testing in pheochromocytoma or functional paraganglioma. J. Clin. Oncol. 23, 8812-8818 (2005).
22. Lenders, J. W. et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99, 1915-1942 (2014).
23. Niemann, S. & Muller, U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat. Genet. 26, 268-270 (2000).
24. Burnichon, N. et al. SDHA is a tumor suppressor gene causing paraganglioma. Hum. Mol. Genet. 19, 3011-3020 (2010).
25. Astuti, D. et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am. J. Hum. Genet. 69, 49-54 (2001).
26. Hao, H. X. et al. SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science 325, 1139-1142 (2009).
27. Pollard, P. J. et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1 in tumours which result from germline FH and SDH mutations. Hum. Mol. Genet. 14, 2231-2239 (2005).
28. Briere, J. J. et al. Mitochondrial succinate is instrumental for HIF1 nuclear translocation in SDHA-mutant fibroblasts under normoxic conditions. Hum. Mol. Genet. 14, 3263-3269 (2005).
29. Letouze, E. et al. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell 23, 739-752 (2013).
30. Baysal, B. E. Mitochondrial complex II and genomic imprinting in inheritance of paraganglioma tumors. Biochim. Biophys. Acta 1827, 573-577 (2013).
31. Pasini, B. & Stratakis, C. A. SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes. J. Intern. Med. 266, 19-42 (2009).
32. Gimenez-Roqueplo, A. P. et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res. 63, 5615-5621 (2003).
33. Amar, L. et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J. Clin. Endocrinol. Metab. 92, 3822-3828 (2007).
34. Else, T. et al. The clinical phenotype of SDHC-associated hereditary paraganglioma syndrome (PGL3). J. Clin. Endocrinol. Metab. 99, E1482-E1486 (2014).
35. Ricketts, C. et al. Germline SDHB mutations and familial renal cell carcinoma. J. Natl Cancer Inst. 100, 1260-1262 (2008).
36. Pasini, B. et al. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur. J. Hum. Genet. 16, 79-88 (2008).
37. Qin, Y. et al. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat. Genet. 42, 229-233 (2010).
38. Comino-Mendez, I. et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat. Genet. 43, 663-667 (2011).
39. Qin, Y. et al. The tumor susceptibility gene TMEM127 is mutated in renal cell carcinomas and modulates endolysosomal function. Hum. Mol. Genet. 23, 2428-2439 (2014).
40. Cascon, A. & Robledo, M. MAX and MYC: a heritable breakup. Cancer Res. 72, 3119-3124 (2012).
41. Abermil, N. et al. TMEM127 screening in a large cohort of patients with pheochromocytoma and/or paraganglioma. J. Clin. Endocrinol. Metab. 97, E805-E809 (2012).
42. Burnichon, N. et al. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin. Cancer Res. 18, 2828-2837 (2012).
43. Zhuang, Z. et al. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N. Engl. J. Med. 367, 922-30 (2012).
44. Buffet, A. et al. Mosaicism in HIF2A-related polycythemia-paraganglioma syndrome. J. Clin. Endocrinol. Metab. 99, E369-E373 (2014).
45. Schlisio, S. et al. The kinesin KIF1B acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev. 22, 884-93 (2008).
46. Ladroue, C. et al. Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia. Haematologica 97, 9-14 (2012).
47. Gaal, J. et al. Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas. J. Clin. Endocrinol. Metab. 95, 1274-1278 (2010).
48. Crona, J. et al. Somatic mutations in HRAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing. J. Clin. Endocrinol. Metab. 98, E1266-E1271 (2013).
49. Oudijk, L. et al. HRAS mutations are restricted to sporadic pheochromocytomas lacking specific clinical or pathological features: data from a multi-institutional series. J. Clin. Endocrinol. Metab. 99, E1376-E1380 (2014).
50. van Hulsteijn, L. T., Dekkers, O. M., Hes, F. J., Smit, J. W. & Corssmit, E. P. Risk of malignant paraganglioma in SDHB-mutation and SDHD-mutation carriers: a systematic review and meta-analysis. J. Med. Genet. 49, 768-776 (2012).
51. King, K. S. et al. Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. J. Clin. Oncol. 29, 4137-4142 (2011).
52. Lenders, J. W. et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 287, 1427-1434 (2002).
53. Peitzsch, M. et al. Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatography-tandem mass spectrometry: utility for diagnosis of dopamine-producing metastatic phaeochromocytoma. Ann. Clin. Biochem. 50, 147-155 (2013).
54. van Nederveen, F. H. et al. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol. 10, 764-771 (2009).
55. Korpershoek, E. et al. SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J. Clin. Endocrinol. Metab. 96, E1472-E1476 (2011).
56. Bardella, C. et al. Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status. J. Pathol. 225, 4-11 (2011).
57. Crona, J. et al. Next-generation sequencing in the clinical genetic screening of patients with pheochromocytoma and paraganglioma. Endocr. Connect. 2, 104-111 (2013).
58. Welander, J. et al. Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma. J. Clin. Endocrinol. Metab. 99, E1352-E1360 (2014).
59. McInerney-Leo, A. M. et al. Whole exome sequencing is an efficient and sensitive method for detection of germline mutations in patients with phaeochromcytomas and paragangliomas. Clin. Endocrinol. (Oxf.) 80, 25-33 (2014).
60. MacArthur, D. G. et al. Guidelines for investigating causality of sequence variants in human disease. Nature 508, 469-476 (2014).
61. Canu, L. et al. Pitfalls in genetic analysis of pheochromocytomas/paragangliomas - case report. J. Clin. Endocrinol. Metab. 99, 2321-2326 (2014).
62. Gimenez-Roqueplo, A. P. et al. Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA Investigators. J. Clin. Endocrinol. Metab. 98, E162-E173 (2013).
63. Kaji, P. et al. The role of 6-18F-fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome. Eur. J. Endocrinol. 156, 483-487 (2007).
64. Taieb, D. et al. EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur. J. Nucl. Med. Mol. Imaging 39, 1977-1995 (2012).
65. Timmers, H. J. et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J. Clin. Endocrinol. Metab. 94, 4757-4767 (2009).
66. Walz, M. K. Adrenalectomy for preservation of adrenocortical function. Indication and results [German]. Chirurg. 80, 99-104 (2009).
67. Grubbs, E. G. et al. Long-term outcomes of surgical treatment for hereditary pheochromocytoma. J. Am. Coll. Surg. 216, 280-289 (2013).
68. Alesina, P. F. et al. Minimally invasive cortical-sparing surgery for bilateral pheochromocytomas. Langenbecks Arch. Surg. 397, 233-238 (2012).
69. Rohmer, V. et al. Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: a multicenter study of the Groupe Francais d'Etude des Tumeurs Endocrines. J. Clin. Endocrinol. Metab. 96, E509-E518 (2011).
70. Thosani, S. et al. The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2. J. Clin. Endocrinol. Metab. 98, E1813-E1819 (2013).
71. Bickmann, J. K. et al. Phenotypic variability and risk of malignancy in SDHC-linked paragangliomas: lessons from 3 unrelated cases with an identical germline mutation (p.Arg133∗). J. Clin. Endocrinol. Metab. 99, E489-E496 (2014).
72. Jasperson, K. W. et al. Role of rapid sequence whole-body MRI screening in SDH-associated hereditary paraganglioma families. Fam. Cancer 13, 257-265 (2014).
73. Timmers, H. J. et al. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J. Natl Cancer Inst. 104, 700-708 (2012).
74. Eisenhofer, G. et al. Distinct gene expression profiles in norepinephrine-and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocr. Relat. Cancer 11, 897-911 (2004).
75. Dahia, P. L. et al. A HIF1- regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet. 1, 72-80 (2005).
76. Favier, J. et al. The Warburg effect is genetically determined in inherited pheochromocytomas. PLoS ONE 4, e7094 (2009).
77. Lopez-Jimenez, E. et al. Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol. Endocrinol. 24, 2382-2391 (2010).
78. Favier, J., Buffet, A. & Gimenez-Roqueplo, A. P. HIF2A mutations in paraganglioma with polycythemia. N. Engl. J. Med. 367, 2161 (2012).
79. Welander, J. et al. Integrative genomics reveals frequent somatic NF1 mutations in sporadic pheochromocytomas. Hum. Mol. Genet. 21, 5406-5416 (2012).
80. Joshua, A. M. et al. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. J. Clin. Endocrinol. Metab. 94, 5-9 (2009).
81. Jimenez, C. et al. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J. Clin. Endocrinol. Metab. 94, 386-391 (2009).
82. Hahn, N. M. et al. Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malate. J. Clin. Oncol. 27, 460-463 (2009).
83. Ayala-Ramirez, M. et al. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J. Clin. Endocrinol. Metab. 97, 4040-4050 (2012).
84. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01371201 (2012).
85. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00843037 (2013).
86. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01967576 (2014).
87. Bergers, G. & Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8, 592-603 (2008).
88. Druce, M. R., Kaltsas, G. A., Fraenkel, M., Gross, D. J. & Grossman, A. B. Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001). Horm. Metab. Res. 41, 697-702 (2009).
89. Oh, D. Y. et al. Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas. Cancer 118, 6162-6170 (2012).
90. Giubellino, A. et al. Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice. Endocrinology 154, 646-655 (2013).
91. Killian, J. K. et al. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov. 3, 648-657 (2013).
92. Loriot, C. et al. Epithelial to mesenchymal transition is activated in metastatic pheochromocytomas and paragangliomas caused by SDHB gene mutations. J. Clin. Endocrinol. Metab. 97, E954-E962 (2012).
93. Hadoux, J. et al. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int. J. Cancer 135, 2711-2720 (2014).
94. Cameron, E. & Pauling, L. Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc. Natl Acad. Sci. USA 75, 4538-4542 (1978).